Overall, our study clearly configures a potential targeted signaling axis linking CAFs and ccRCC cancer cells, providing a rationale to develop FGF7-targeted therapy against ccRCC progression. The gene discussed is FGF7; the disease is nonpapillary renal cell carcinoma.